Generic Qinlock Availability

Last updated on Sep 11, 2024.

Qinlock is a brand name of ripretinib, approved by the FDA in the following formulation(s):

QINLOCK (ripretinib - tablet;oral)

Manufacturer: DECIPHERA PHARMS
Approval date: May 15, 2020
Strength(s): 50MG ^[RLD]

Has a generic version of Qinlock been approved?

No. There is currently no therapeutically equivalent version of Qinlock available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qinlock. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Methods of treating gastrointestinal stromal tumors
Patent 10,966,966
Issued: April 6, 2021
Inventor(s): Soto Rodrigo Ruiz & Rosen Oliver & Pitman Jama
Assignee(s): Deciphera Pharmaceuticals, LLC
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
Amorphous kinase inhibitor formulations and methods of use thereof
Patent 11,185,535
Issued: November 30, 2021
Inventor(s): Kaufman Michael D. & Bone Scott & Bloom Corey & Jordan Fred
Assignee(s): Deciphera Pharmaceuticals, LLC
Provided herein is an amorphous compound represented by Formula (I):
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Methods of treating gastrointestinal stromal tumors
Patent 11,266,635
Issued: March 8, 2022
Inventor(s): Soto Rodrigo Ruiz & Rosen Oliver & Pitman Jama
Assignee(s): Deciphera Pharmaceuticals, LLC
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME
Patent 11,344,536
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION
Patent 11,395,818
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Methods of treating gastrointestinal stromal tumors
Patent 11,426,390
Issued: August 30, 2022
Inventor(s): Soto Rodrigo Ruiz & Rosen Oliver & Pitman Jama
Assignee(s): Deciphera Pharmaceuticals, LLC
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH A CYP3A4 INHIBITOR
Methods of treating gastrointestinal stromal tumors
Patent 11,433,056
Issued: September 6, 2022
Inventor(s): Soto Rodrigo Ruiz & Rosen Oliver & Pitman Jama
Assignee(s): Deciphera Pharmaceuticals, LLC
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: METHOD OF TREATING GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 MYALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent 11,529,336
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM A GRADE 3 ADVERSE REACTION WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent 11,534,432
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED AT LEAST THREE TYROSINE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB
Patent 11,576,903
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,576,904
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent 11,612,591
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,779,572
Patent expiration dates:
- October 6, 2042
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS HAVING PRE-EXISTING SEVERE HEPATIC IMPAIRMENT AND SUFFERING FROM AN ADVERSE EVENT WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent 11,793,795
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,801,237
Patent expiration dates:
- December 30, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
  ✓
  Drug product
Patent 11,813,251
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH A WILD TYPE KIT MUTATION IN PATIENTS PREVIOUSLY ADMINISTERED THREE OR MORE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB
Patent 11,844,788
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,850,240
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,850,241
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,896,585
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,903,933
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,911,370
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,918,564
Patent expiration dates:
- December 30, 2040
  ✓
  Drug product
Patent 11,969,414
Patent expiration dates:
- February 8, 2041
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH ITRACONAZOLE
Patent 11,969,415
Patent expiration dates:
- December 30, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Patent 12,023,325
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED IMATINIB
Patent 12,023,326
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN A PATIENT SUFFERING FROM GRADE 2 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent 12,023,327
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED 4 LINES OF PRIOR THERAPY, WHERE THE FIRST LINE OF PRIOR THERAPY IS IMATINIB
Patent 12,023,328
Patent expiration dates:
- December 30, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR COMPRISING ADMINISTERING ONCE DAILY, ONE OR MORE TABLETS COMPRISING RIPRETINIB
Patent 12,059,410
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
Patent 12,059,411
Patent expiration dates:
- August 12, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME
Patent 12,064,422
Patent expiration dates:
- December 30, 2040
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent 8,188,113
Issued: May 29, 2012
Inventor(s): Flynn Daniel L. & Petillo Peter A. & Kaufman Michael D. & Patt William C.
Assignee(s): Deciphera Pharmaceuticals, Inc.
The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.
Patent expiration dates:
- July 27, 2030
  ✓
  Drug substance
  ✓
  Drug product
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent 8,461,179
Issued: June 11, 2013
Inventor(s): Flynn Daniel L. & Kaufman Michael D. & Petillo Peter A.
Assignee(s): Deciphera Pharmaceuticals, LLC
The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.
Patent expiration dates:
- May 15, 2034
  ✓
  Drug substance
  ✓
  Drug product
Patent RE48731
Patent expiration dates:
- June 7, 2032
  ✓
  Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- May 15, 2025 - NEW CHEMICAL ENTITY
- May 15, 2027 - INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB

More about Qinlock (ripretinib)

Patient resources

Qinlock drug information

Professional resources

Related treatment guides

Gastrointestinal Stromal Tumor

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

User Reviews & Ratings

Review this drug

Images

Pill DC1 is Qinlock 50 mg — Qinlock 50 mg (DC1)